膜杰作
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax
> 【LILRA4】
LILRA4信息
英文名称：Leukocyte immunoglobulin-like receptor subfamily A member 4
中文名称：人白细胞免疫球蛋白样受体亚家族A成员4
靶点别称：
中文名称：人白细胞免疫球蛋白样受体亚家族A成员4
靶点别称：
上市药物数量：0
临床药物数量：1
最高研发阶段：临床一期
临床药物数量：1
最高研发阶段：临床一期
LILRA4产品列表
| 货号 | 物种 | 产品描述 | 蛋白结构 | 纯度 | 活性 |
|---|---|---|---|---|---|
| LI4-H5243 |
 Human |
Human LILRA4 / CD85g / ILT7 Protein, His Tag (MALS verified) |
 |
  |
评论(0)
LILRA4 分子别名
LILRA4,CD85g,ILT7,ILT-7
LILRA4 分子背景
Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.
LILRA4 前沿进展
LILRA4临床药物信息
| 英文名称 | 研发代码 | 研发阶段 | 公司 | 适应症 | 临床试验 |
|---|
